JP2010523682A - 癌及び他の疾患の治療に有用なカルボリン誘導体の投与 - Google Patents

癌及び他の疾患の治療に有用なカルボリン誘導体の投与 Download PDF

Info

Publication number
JP2010523682A
JP2010523682A JP2010503086A JP2010503086A JP2010523682A JP 2010523682 A JP2010523682 A JP 2010523682A JP 2010503086 A JP2010503086 A JP 2010503086A JP 2010503086 A JP2010503086 A JP 2010503086A JP 2010523682 A JP2010523682 A JP 2010523682A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
alkoxy
aryl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523682A5 (cg-RX-API-DMAC7.html
Inventor
カオ リアングクイアン
ヒラワト サミト
ミルレル ラングドン
エル．エルフリング ガリ
ダビス トホマス
エル．ウエエタルル マリア
Original Assignee
ピーティーシー セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーティーシー セラピューティクス，インコーポレーテッド filed Critical ピーティーシー セラピューティクス，インコーポレーテッド
Publication of JP2010523682A publication Critical patent/JP2010523682A/ja
Publication of JP2010523682A5 publication Critical patent/JP2010523682A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2010503086A 2007-04-13 2008-04-12 癌及び他の疾患の治療に有用なカルボリン誘導体の投与 Pending JP2010523682A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91161207P 2007-04-13 2007-04-13
PCT/US2008/004809 WO2008127714A1 (en) 2007-04-13 2008-04-12 Administration of carboline derivatives useful in the treatment of cancer and other diseases

Publications (2)

Publication Number Publication Date
JP2010523682A true JP2010523682A (ja) 2010-07-15
JP2010523682A5 JP2010523682A5 (cg-RX-API-DMAC7.html) 2011-10-20

Family

ID=39618825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503086A Pending JP2010523682A (ja) 2007-04-13 2008-04-12 癌及び他の疾患の治療に有用なカルボリン誘導体の投与

Country Status (6)

Country Link
US (1) US20100158858A1 (cg-RX-API-DMAC7.html)
EP (1) EP2139476A1 (cg-RX-API-DMAC7.html)
JP (1) JP2010523682A (cg-RX-API-DMAC7.html)
AU (1) AU2008239598A1 (cg-RX-API-DMAC7.html)
CA (1) CA2683444A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008127714A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503065A (ja) * 2007-11-08 2011-01-27 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための方法及び組成物
JP2012528192A (ja) * 2009-05-27 2012-11-12 ピーティーシー セラピューティクス，インコーポレーテッド がん及び非新生物性状態の治療方法
WO2017073743A1 (ja) * 2015-10-30 2017-05-04 協和発酵キリン株式会社 三環性化合物
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076353B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7601840B2 (en) * 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
WO2010138659A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
US8703726B2 (en) 2009-05-27 2014-04-22 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US20120157401A1 (en) * 2009-05-27 2012-06-21 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
EP2435437A4 (en) 2009-05-27 2012-10-31 Ptc Therapeutics Inc PROCESSES FOR THE PREPARATION OF SUBSTITUTED TETRAHYDRO BETA-CARBOLINES
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
PT3004090T (pt) 2013-05-28 2017-12-22 Astrazeneca Ab Compostos químicos
US10307406B2 (en) 2013-08-31 2019-06-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for re-activating Epstein-Barr virus and screening compounds therefor
CA2952897A1 (en) 2014-06-27 2015-12-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
RS60824B1 (sr) 2014-12-18 2020-10-30 Hoffmann La Roche Tetrahidro-pirido[3,4-b]indoli kao modulatori estrogenih receptora i njihova upotreba
KR20220071293A (ko) 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
EP3554494A4 (en) 2016-12-19 2021-02-17 Cellixbio Private Limited COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION
US10519152B2 (en) * 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
PL3810283T3 (pl) 2018-06-21 2023-10-16 F. Hoffmann-La Roche Ag Postacie stałe soli winianowej 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropylo)azetydyn-3-ylo)amino)fenylo)-3-metylo-1,3,4,9-tetrahydro-2H-pirydo[3,4-b]indol-2-ilo)-2,2-difluoropropan-1-olu, sposób ich otrzymywania i sposoby ich zastosowania w leczeniu nowotworów
US20210205225A1 (en) 2018-08-03 2021-07-08 Ptc Therapeutics, Inc. Bioavailable oral dosage forms
AU2019340402B2 (en) 2018-08-17 2025-04-03 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
CA3126163A1 (en) 2019-01-15 2020-07-23 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia
KR20220044528A (ko) 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
JP2024502270A (ja) 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬
WO2023230587A2 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113703A2 (en) * 2005-04-18 2006-10-26 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US282849A (en) * 1883-08-07 Fruit-jar
US272759A (en) * 1883-02-20 Desk-top
US254878A (en) * 1882-03-14 Train-boat
US40527A (en) * 1863-11-03 Improvement in cooking-stoves
US64683A (en) * 1867-05-14 mason and joseph messinger
AU2001283964A1 (en) * 2000-08-09 2002-02-18 Pharmacia And Upjohn Company Composition for combined use of aromatase inhibitors
AU2002249890A1 (en) * 2001-02-12 2002-08-28 Lilly Icos Llc Carboline derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113703A2 (en) * 2005-04-18 2006-10-26 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503065A (ja) * 2007-11-08 2011-01-27 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための方法及び組成物
JP2014205690A (ja) * 2007-11-08 2014-10-30 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための医薬組成物
JP2016104767A (ja) * 2007-11-08 2016-06-09 ザ ジェネラル ホスピタル コーポレイション 蛋白尿症の治療のための方法及び組成物
JP2012528192A (ja) * 2009-05-27 2012-11-12 ピーティーシー セラピューティクス，インコーポレーテッド がん及び非新生物性状態の治療方法
US11613538B2 (en) 2009-05-27 2023-03-28 Ptc Therapeutics, Inc. Method of inhibiting or reducing a viral infection
WO2017073743A1 (ja) * 2015-10-30 2017-05-04 協和発酵キリン株式会社 三環性化合物
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers

Also Published As

Publication number Publication date
WO2008127714A1 (en) 2008-10-23
AU2008239598A1 (en) 2008-10-23
EP2139476A1 (en) 2010-01-06
US20100158858A1 (en) 2010-06-24
CA2683444A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
JP2010523682A (ja) 癌及び他の疾患の治療に有用なカルボリン誘導体の投与
WO2008127715A1 (en) Carboline derivatives useful in the treatment of cancer and other diseases
JP4857452B2 (ja) 血管新生の抑制に有用なカルボリン誘導体
US8372860B2 (en) Carboline derivatives useful in the inhibition of angiogenesis
US8697662B2 (en) Methods for treating Kaposi sarcoma
RU2640485C2 (ru) Комбинированное лечение рака
EP1732543B1 (en) Tetracyclic carboline deratives for inhibiting angiogenesis
JP7223998B2 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
US20100173873A1 (en) Treatment of metastasized tumors
US8299081B2 (en) Methods for treating drug resistant cancer
TW200524595A (en) Methods for treating IGF1R-inhibitor induced hyperglycemia
JP2000128785A (ja) うっ血性心不全を治療する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140218